Literature DB >> 15990223

Localization of the ABCG2 mitoxantrone resistance-associated protein in normal tissues.

Patricia A Fetsch1, Andrea Abati, Thomas Litman, Kuniaki Morisaki, Yasumasa Honjo, Khush Mittal, Susan E Bates.   

Abstract

Reduced drug accumulation due to overexpression of individual members of the ATP binding cassette (ABC) superfamily of membrane transporters has been investigated as a cause of multidrug resistance and treatment failure in oncology. This study was designed to develop an immunohistochemical assay to determine the expression and localization of the 72kDa ABC half-transporter ABCG2 in normal tissues. Formalin-fixed, paraffin embedded archival tissue from 31 distinct normal tissues with an average of eight separate tissue samples of each were immunostained with rabbit-anti-ABCG2 antibody 405 using a modified avidin-biotin procedure. As a negative control, each sample was also stained with antibody pre-adsorbed with peptide to assess background staining. As a means of verification, selected tissues were also stained with the commercially available monoclonal antibody 5D3. ABCG2 positivity was consistently found in alveolar pneumocytes, sebaceous glands, transitional epithelium of bladder, interstitial cells of testes, prostate epithelium, endocervical cells of uterus, squamous epithelium of cervix, small and large intestinal mucosa/epithelial cells, islet and acinar cells of pancreas, zona reticularis layer of adrenal gland, kidney cortical tubules and hepatocytes. Placental syncytiotrophoblasts showed both cytoplasmic and surface staining. Our results support a hypothesis concluding that ABCG2 plays a role in the protection of organs from cytotoxins. However, many of the cell types expressing ABCG2 have a significant secretory function. These data suggest a dual function for ABCG2 in some tissues: the excretion of toxins and xenobiotics including anti-cancer agents and a potential, as-yet undefined role in the secretion of endogenous substrates.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15990223     DOI: 10.1016/j.canlet.2005.04.024

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  53 in total

Review 1.  The controversial role of ABC transporters in clinical oncology.

Authors:  Akina Tamaki; Caterina Ierano; Gergely Szakacs; Robert W Robey; Susan E Bates
Journal:  Essays Biochem       Date:  2011-09-07       Impact factor: 8.000

Review 2.  Transporters at CNS barrier sites: obstacles or opportunities for drug delivery?

Authors:  Lucy Sanchez-Covarrubias; Lauren M Slosky; Brandon J Thompson; Thomas P Davis; Patrick T Ronaldson
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

3.  Identification of compounds that correlate with ABCG2 transporter function in the National Cancer Institute Anticancer Drug Screen.

Authors:  John F Deeken; Robert W Robey; Suneet Shukla; Kenneth Steadman; Arup R Chakraborty; Balasubramanian Poonkuzhali; Erin G Schuetz; Susan Holbeck; Suresh V Ambudkar; Susan E Bates
Journal:  Mol Pharmacol       Date:  2009-07-24       Impact factor: 4.436

4.  Coexpression of ABCB1 and ABCG2 in a Cell Line Model Reveals Both Independent and Additive Transporter Function.

Authors:  Andrea N Robinson; Bethelihem G Tebase; Sonia C Francone; Lyn M Huff; Hanna Kozlowski; Dominique Cossari; Jung-Min Lee; Dominic Esposito; Robert W Robey; Michael M Gottesman
Journal:  Drug Metab Dispos       Date:  2019-05-02       Impact factor: 3.922

5.  Structure of the human multidrug transporter ABCG2.

Authors:  Nicholas M I Taylor; Ioannis Manolaridis; Scott M Jackson; Julia Kowal; Henning Stahlberg; Kaspar P Locher
Journal:  Nature       Date:  2017-05-29       Impact factor: 49.962

Review 6.  Oral anticancer drugs: mechanisms of low bioavailability and strategies for improvement.

Authors:  Frederik E Stuurman; Bastiaan Nuijen; Jos H Beijnen; Jan H M Schellens
Journal:  Clin Pharmacokinet       Date:  2013-06       Impact factor: 6.447

7.  Substrate affinity of photosensitizers derived from chlorophyll-a: the ABCG2 transporter affects the phototoxic response of side population stem cell-like cancer cells to photodynamic therapy.

Authors:  Janet Morgan; Jennifer D Jackson; Xiang Zheng; Suresh K Pandey; Ravindra K Pandey
Journal:  Mol Pharm       Date:  2010-09-01       Impact factor: 4.939

8.  hsa-miR-520h downregulates ABCG2 in pancreatic cancer cells to inhibit migration, invasion, and side populations.

Authors:  F Wang; X Xue; J Wei; Y An; J Yao; H Cai; J Wu; C Dai; Z Qian; Z Xu; Y Miao
Journal:  Br J Cancer       Date:  2010-07-13       Impact factor: 7.640

9.  Study on like-stem characteristics of tumor sphere cells in human gastric cancer line HGC-27.

Authors:  Wei-Hong Shi; Cong Li; Jin-Jing Liu; Zheng-Li Wei; Jia Liu; Wan-Wei Dong; Wei Yang; Wei Wang; Zhi-Hong Zheng
Journal:  Int J Clin Exp Med       Date:  2015-10-15

10.  Vandetanib (Zactima, ZD6474) antagonizes ABCC1- and ABCG2-mediated multidrug resistance by inhibition of their transport function.

Authors:  Li-sheng Zheng; Fang Wang; Yu-hong Li; Xu Zhang; Li-ming Chen; Yong-ju Liang; Chun-ling Dai; Yan-yan Yan; Li-yang Tao; Yan-jun Mi; An-kui Yang; Kenneth Kin Wah To; Li-wu Fu
Journal:  PLoS One       Date:  2009-04-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.